New CoolCure Concrete Admixture converts typical cement into a Type IV, low-heat cement resulting in up to 80% less heat and 50% greater strength. CoolCure is a revolutionary new technology that ...
SUGAR LAND, Texas, Dec. 13, 2018 /PRNewswire/ -- QuVa Pharma, Inc. a leading FDA registered 503B outsourcing provider of "ready-to-use" compounded I.V. products, announced today that it has been ...
The hospital estimates its switch to the Vial2Bag needle-free IV admixture system will save more than $160,000 per year in reduced labor and product costs. The ease of access to critical medications ...
MISSISSAUGA, ON, Nov. 4, 2014 /CNW/ - Baxter Corporation today announced it is investing $10 million to build a new facility in Mississauga, Ontario for its Centralized Intravenous Admixing Pharmacy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback